Biosidus, an Argentina-based biotechnology company, announced on Wednesday the signing of a licensing and supply agreement with Mubadala Bio, the life sciences platform of Mubadala Investment Company, to introduce a portfolio of biologic therapies in the United Arab Emirates through DiabTec, Mubadala Bio's biologics platform.

The collaboration includes biologic therapies across endocrinology, nephrology and oncology, including epoetin alfa, filgrastim, interferon beta and somatropin.

The agreement was signed during BIO International Convention 2026.